NORWOOD, MA, MAY 21, 2009 – Molecular Biometrics, Inc., a privately-held metabolomics company developing novel clinical tools to more accurately characterize biologic function in health and disease, today announced it received the 2009 Genesis Technology Transfer Award, presented by BIOQuebec. The company’s technology platform, which uses Near Infrared Spectroscopy (NIRS) to analyze molecular biomarkers for assisted reproduction and infertility, Alzheimer’s disease and Parkinson’s disease, includes technology that was licensed from McGill University in Montreal, Canada.

“We are honored to be recognized for our innovation by BIOQuebec, as we initiate the commercial launch of our lead product, ViaMetrics-E™, a novel diagnostic procedure used to evaluate embryo viability for in vitro fertilization,” said James T. Posillico, PhD, President and Chief Executive Officer, Molecular Biometrics. “Through the exceptional work of our highly specialized team, we have developed and validated the technology, and begun manufacturing and introduction of ViaMetrics-E in several key markets around the world.”

Established in 1991, BIOQuebec is the largest network of bio-industries and life sciences organizations in Canada. The Genesis Awards recognize outstanding achievements of individuals and companies who played a key role in the growth of Quebec’s life sciences industry. The Genesis Technology Transfer Award was sponsored by Centre Quebecois de Valorisation des Biotechnologies, a liaison and transfer center, that aims to stimulate and support technology transfer and innovation within small to medium-sized bio-industry companies in Quebec.

Metabolomics is a complex scientific process that identifies and measures individual signals from many small molecular compounds produced by cellular metabolism which, when evaluated systematically, represent unique biomarkers of biologic function in health and disease.

Molecular Biometrics developed a proprietary NIRS platform for its metabolomic applications. NIRS is a robust technology that rapidly measures the vibrational energy produced by small molecule functional groups, creating a unique profile of molecules that are reflective of cellular function and viability.

The spectral signatures are further analyzed by proprietary bioinformatics and chemometric algorithms that allows for the creation of a novel “metabolomic profile” or “fingerprint” that can be used to systematically distinguish between the often subtle differences that separate normal physiology from the onset or progression of disease, or an individual’s response to therapeutic intervention.

Molecular Biometrics, Inc. is applying novel metabolomic technologies to develop accurate, non-invasive clinical tools for use in personalized medicine to evaluate normal biologic function in health and in disease, and for drug discovery and development. The company’s proprietary technology is being applied in reproductive health, IVF and neurodegenerative disease (e.g., Parkinson’s disease). Molecular Biometrics is headquartered in Norwood, MA, with research and development facilities in New Haven, CT, and Montreal, Quebec. For more information, please visit www.molecularbiometrics.com.

CONTACT: Gina Cella
Cella Communications
C: 781-799-3137
O: 781-334-4692
ginacella@comcast.net